New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc. (PASG) vs Psyence Biomedical Ltd. (PBM)

Passage Bio, Inc. and Psyence Biomedical Ltd. are both Biotechnology companies. Passage Bio, Inc. and Psyence Biomedical Ltd. are of similar size ($11.6M and $10.9M). Passage Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Psyence Biomedical Ltd. trades at 0.1×. Across the 9 metrics below, Psyence Biomedical Ltd. leads on 5 and Passage Bio, Inc. on 4.

Valuation

Metric PASG PBM Biotechnology median
P/E n/m 0.13 8.49
P/S — — 8.56
P/B 253.58 0.06 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.21 1.94 0.69
EV/Sales — — 8.00
Earnings yield (262.60%) 772.85% (35.81%)
Free cash flow yield (257.29%) (1,167.29%) (25.41%)

Profitability

Metric PASG PBM Biotechnology median
Gross margin — — 70.18%
Operating margin — — 0.00%
Net margin — — 0.00%
Free cash flow margin — — 0.00%
Return on equity (212.27%) 1.55% (51.58%)
Return on assets (69.68%) 1.45% (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric PASG PBM Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) 32.94% (138.35%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric PASG PBM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.00 8.09 4.79
Net debt to EBITDA 0.96 1.20 1.01

Dividend

Metric PASG PBM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PASG PBM Biotechnology median
Market cap 11.62m 10.91m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack